Therapeutic potential of MSCs and their exosomes in hepatic Ischaemia-Reperfusion injury: a systematic review and meta-analysis of rodent studies
Mu Y., Zhu W., Ma W., Cheng Y., Ren B., Cheng Y.
Meta-analysis, published in Stem Cells Transl Med (2026) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- Stem Cells Transl Med (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41582651
- PMCID
- PMC12832943
- DOI
- 10.1093/stcltm/szaf078
Abstract (original English)
Objective This meta-analysis comprehensively evaluates the therapeutic efficacy and mechanisms of mesenchymal stem cells (MSCs) and their exosomes in rodent models of hepatic ischemia-reperfusion injury (HIRI), providing preclinical support for future clinical translation. Methods In accordance with the PRISMA guidelines, we systematically searched PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov for studies published from inception to January 13, 2025, and identified 64 eligible studies. Risk of bias was evaluated using the SYRCLE tool, and Review Manager 5.4.1 was employed for meta-analysis, calculating SMD and 95%CI. Primary outcomes included liver function (ALT/AST), histopathological scores (Suzuki's score, necrotic area ratio), inflammatory cytokines (TNF-α), and apoptosis markers (c-caspase 3). Results MSCs and their exosomes significantly ameliorated HIRI. In the 60-minute ischemia group, ALT (SMD = 3.49, P Conclusion MSCs and their exosomes mitigate HIRI through multi-target mechanisms but requires standardized protocols. Future studies should prioritize large-animal validation and translational research to facilitate precision clinical application.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.